Polaris Oncology Survivor Transition (POST) System

Polaris 肿瘤幸存者过渡 (POST) 系统

基本信息

  • 批准号:
    8522845
  • 负责人:
  • 金额:
    $ 23.04万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-05-10 至 2015-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The Institute of Medicine (IOM) strongly recommends that all breast cancer patients who are ending active treatment have a "survivorship plan." Such a plan should assist patients in moving back to their primary care physician (PCP), provide advice for reducing risk for cancer recurrence or new cancer development, and address the remaining psychosocial challenges and aftereffects of cancer and cancer treatment. However, because oncology providers are usually very busy, a comprehensive plan is often neglected. This has taken on heightened urgency because new standards published by American College of Surgeons (ACS) require evidence of survivorship planning for accreditation beginning in 2015. Polaris Health Directions (Small Business) and the University of Massachusetts Medical School (UMass, Research Institute) have partnered to solve the problem of poor survivorship planning with the Polaris Oncology Survivor Transition (POST) system. The POST will blend input from the oncology team and a patient self-assessment to create versions of a Survivorship Plan for the oncology provider, PCP, and patient. Each version will contain the following components, but the length and specific content will be dictated by the needs of the end-user: (1) a medical history and oncology treatment summary; (2) a medical plan that lists testing and medical appointments for the next 12 months; (3) personally tailored educational information and referrals related to psychosocial and physical functioning, including the option of a faxed referral to mental health provider for those reporting significant distress; (4) recommendations and resource links pertaining to health behaviors that may improve quality of life and reduce the chance of recurrence; and (5) recommendations and referrals for supportive care, including resources to assist with spirituality and financial concerns. Finally, patients will complete updat assessments at follow up oncology appointments, and the Plan will be adjusted based on new information. The specific aims of Phase 1 are to (1) design and build a prototype of the software, and (2) conduct a field test, refining the prototype iteratively with breast cancer patients and their clinicians until the software meets the target evaluation criteria (n~30). The POST is highly innovative as it will be the first system to produce tailored survivorship plans fuly reflecting IOM and ACS requirements. Furthermore, it will be the first survivorship system to communicate bi-directionally with the EHR, to be driven by both provider and patient input, to allow updates to reflect changes in the patient's condition over time, and to encompass both a medical and a psychosocial summary. Since PCPs currently receive little or no information from the oncology team, the POST's transmission of a Survivorship Plan tailored to meet the PCP's needs is pioneering. The POST's commercialization potential is strong as it can lead to improvements in patient health, help providers perform essential functions more easily and assist organizations in complying with the regulatory standards. Polaris has already established a strong presence in the target market with its distress management product.
描述(由申请人提供):医学研究所(IOM)强烈建议所有结束积极治疗的乳腺癌患者都有一个“生存计划”。“这样的计划应该帮助患者回到他们的初级保健医生(PCP),提供减少癌症复发或新癌症发展风险的建议,并解决癌症和癌症治疗的剩余心理社会挑战和后遗症。然而,由于肿瘤学提供者通常非常忙碌,因此通常忽略了全面的计划。这已经变得更加紧迫,因为美国外科医生学会(ACS)发布的新标准要求从2015年开始认证生存计划的证据。北极星健康方向(小企业)和马萨诸塞州医学院大学(马萨诸塞州大学,研究所)合作,以解决与北极星肿瘤幸存者过渡(POST)系统生存规划差的问题。POST将融合肿瘤团队的输入和患者自我评估,为肿瘤提供者、PCP和患者创建不同版本的生存计划。每个版本将包含以下组成部分,但长度和具体内容将根据最终用户的需要而定:(1)病史和肿瘤治疗摘要;(2)列出未来12个月检查和医疗预约的医疗计划;(3)与心理社会和身体功能有关的个人定制教育信息和转介,包括为那些报告严重痛苦的人提供传真转介给精神卫生提供者的选择;(4)与可能改善生活质量和减少复发机会的健康行为有关的建议和资源链接;以及(5)推荐和转介支持性护理,包括帮助精神和财务问题的资源。最后,患者将在随访肿瘤科预约时完成更新评估,并将根据新信息调整计划。第1阶段的具体目标是(1)设计和构建软件原型,以及(2)进行现场测试,与乳腺癌患者及其临床医生反复完善原型,直到软件满足目标评价标准(n~30)。POST是高度创新的,因为它将是第一个生成完全反映IOM和ACS要求的定制生存计划的系统。此外,它将是第一个与EHR双向通信的生存系统,由提供者和患者输入驱动,允许更新以反映患者状况随时间的变化,并包含医疗和心理总结。由于PCP目前很少或根本没有收到来自肿瘤团队的信息,POST为满足PCP的需求而定制的生存计划的传输是开创性的。POST的商业化潜力很大,因为它可以改善患者健康,帮助提供者更容易地执行基本功能,并协助组织遵守监管标准。北极星已经建立了一个强大的存在,在目标市场与其遇险管理产品。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Erin Lee O'Hea其他文献

Erin Lee O'Hea的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Erin Lee O'Hea', 18)}}的其他基金

Polaris Oncology Survivor Transition (POST) System
Polaris 肿瘤幸存者过渡 (POST) 系统
  • 批准号:
    8831358
  • 财政年份:
    2013
  • 资助金额:
    $ 23.04万
  • 项目类别:
Polaris Oncology Survivor Transition (POST) System
Polaris 肿瘤幸存者过渡 (POST) 系统
  • 批准号:
    9147558
  • 财政年份:
    2013
  • 资助金额:
    $ 23.04万
  • 项目类别:
Polaris Oncology Survivor Transition (POST) System
Polaris 肿瘤幸存者过渡 (POST) 系统
  • 批准号:
    8660664
  • 财政年份:
    2013
  • 资助金额:
    $ 23.04万
  • 项目类别:
EFFECTIVE METHODS FOR DISCLOSING BREAST CANCER DIAGNOSIS
公开乳腺癌诊断的有效方法
  • 批准号:
    7607898
  • 财政年份:
    2007
  • 资助金额:
    $ 23.04万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 23.04万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.04万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 23.04万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.04万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 23.04万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 23.04万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.04万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 23.04万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 23.04万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.04万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了